Fexofenadine hydrochloride

Fexofenadine hydrochloride (CAS 153439-40-8), marketed under the brand name Allegra, is a second-generation antihistamine active pharmaceutical ingredient used in the manufacture of prescription and OTC allergy relief products.

It targets peripheral H1 receptors without significant CNS penetration, making it a preferred API for non-sedating antihistamine formulations. The primary use is in finished oral dosage forms such as tablets and capsules.

These products are indicated for seasonal allergic rhinitis and chronic idiopathic urticaria. Contract manufacturers and generic drug producers source it as the active ingredient in branded and private-label antihistamine products.

In personal care, it is evaluated for inclusion in topical formulations targeting skin hypersensitivity and allergic dermatitis responses. Pharmaceutical formulators also utilize it in pediatric oral suspension development.

Precise particle size and solubility profiles influence grade selection for these liquid applications. Fexofenadine hydrochloride is supplied as a white to off-white crystalline powder for industrial use.

It is available in USP, BP, and Ph. Eur. compendial grades to meet regulatory requirements across major markets. Bulk quantities are typically offered for large scale pharmaceutical manufacturing.

Micronized grades are available to support specific dissolution and bioavailability targets. This ensures the API meets the rigorous standards required for modern drug delivery systems and patient safety protocols.